Search research articles
Contact Us
Filters
Showing results (1-10 of 24) with videos related to
Page
of 3
Sort By:
The Journal of Allergy and Clinical Immunology
|
July 30, 2020
Dissecting the mechanism of action of intravenous immunoglobulin in human autoimmune disease: Lessons from therapeutic modalities targeting Fcγ receptors
Anthony Shock, David Humphreys, Falk Nimmerjahn
International Reviews of Immunology
|
October 23, 2012
CD22 and autoimmune disease
Thomas Dörner, Anthony Shock, Kenneth G C Smith
European Journal of Immunology
|
June 30, 2016
Epratuzumab modulates B-cell signaling without affecting B-cell numbers or B-cell functions in a mouse model with humanized CD22
Lamia Özgör, Carolin Brandl, Anthony Shock, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
November 4, 2021
Pharmacokinetic-pharmacodynamic modelling of the anti-FcRn monoclonal antibody rozanolixizumab: Translation from preclinical stages to the clinic
Rocio Lledo-Garcia, Kate Dixon, Anthony Shock, et al.
Autoimmunity Reviews
|
July 28, 2015
The mechanistic impact of CD22 engagement with epratuzumab on B cell function: Implications for the treatment of systemic lupus erythematosus
Thomas Dörner, Anthony Shock, David M Goldenberg, et al.
Arthritis Research & Therapy
|
May 17, 2017
Targeting CD22 with the monoclonal antibody epratuzumab modulates human B-cell maturation and cytokine production in response to Toll-like receptor 7 (TLR7) and B-cell receptor (BCR) signaling
Natalia V Giltiay, Geraldine L Shu, Anthony Shock, et al.
Neurology(R) Neuroimmunology & Neuroinflammation
|
May 28, 2021
Inhibition of Maternal-to-Fetal Transfer of IgG Antibodies by FcRn Blockade in a Mouse Model of Arthrogryposis Multiplex Congenita
Ester Coutinho, Leslie Jacobson, Anthony Shock, et al.
Arthritis Research & Therapy
|
July 18, 2015
Epratuzumab inhibits the production of the proinflammatory cytokines IL-6 and TNF-α, but not the regulatory cytokine IL-10, by B cells from healthy donors and SLE patients
Vanessa Fleischer, Julia Sieber, Sarah J Fleischer, et al.
Journal of Cell Communication and Signaling
|
April 30, 2016
Engagement of CD22 on B cells with the monoclonal antibody epratuzumab stimulates the phosphorylation of upstream inhibitory signals of the B cell receptor
Simon Lumb, Sarah J Fleischer, Annika Wiedemann, et al.
British Journal of Pharmacology
|
January 25, 2020
Treatment with anti-neonatal Fc receptor (FcRn) antibody ameliorates experimental epidermolysis bullosa acquisita in mice
Anika Kasprick, Maxi Hofrichter, Bryan Smith, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 24) with videos related to
Sort By:
Page
of 3
The Journal of Allergy and Clinical Immunology
|
July 30, 2020
Dissecting the mechanism of action of intravenous immunoglobulin in human autoimmune disease: Lessons from therapeutic modalities targeting Fcγ receptors
Anthony Shock, David Humphreys, Falk Nimmerjahn
International Reviews of Immunology
|
October 23, 2012
CD22 and autoimmune disease
Thomas Dörner, Anthony Shock, Kenneth G C Smith
European Journal of Immunology
|
June 30, 2016
Epratuzumab modulates B-cell signaling without affecting B-cell numbers or B-cell functions in a mouse model with humanized CD22
Lamia Özgör, Carolin Brandl, Anthony Shock, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
November 4, 2021
Pharmacokinetic-pharmacodynamic modelling of the anti-FcRn monoclonal antibody rozanolixizumab: Translation from preclinical stages to the clinic
Rocio Lledo-Garcia, Kate Dixon, Anthony Shock, et al.
Autoimmunity Reviews
|
July 28, 2015
The mechanistic impact of CD22 engagement with epratuzumab on B cell function: Implications for the treatment of systemic lupus erythematosus
Thomas Dörner, Anthony Shock, David M Goldenberg, et al.
Arthritis Research & Therapy
|
May 17, 2017
Targeting CD22 with the monoclonal antibody epratuzumab modulates human B-cell maturation and cytokine production in response to Toll-like receptor 7 (TLR7) and B-cell receptor (BCR) signaling
Natalia V Giltiay, Geraldine L Shu, Anthony Shock, et al.
Neurology(R) Neuroimmunology & Neuroinflammation
|
May 28, 2021
Inhibition of Maternal-to-Fetal Transfer of IgG Antibodies by FcRn Blockade in a Mouse Model of Arthrogryposis Multiplex Congenita
Ester Coutinho, Leslie Jacobson, Anthony Shock, et al.
Arthritis Research & Therapy
|
July 18, 2015
Epratuzumab inhibits the production of the proinflammatory cytokines IL-6 and TNF-α, but not the regulatory cytokine IL-10, by B cells from healthy donors and SLE patients
Vanessa Fleischer, Julia Sieber, Sarah J Fleischer, et al.
Journal of Cell Communication and Signaling
|
April 30, 2016
Engagement of CD22 on B cells with the monoclonal antibody epratuzumab stimulates the phosphorylation of upstream inhibitory signals of the B cell receptor
Simon Lumb, Sarah J Fleischer, Annika Wiedemann, et al.
British Journal of Pharmacology
|
January 25, 2020
Treatment with anti-neonatal Fc receptor (FcRn) antibody ameliorates experimental epidermolysis bullosa acquisita in mice
Anika Kasprick, Maxi Hofrichter, Bryan Smith, et al.
Page
of 3